These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2866293)

  • 1. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.
    Barbeau A; Cloutier T; Roy M; Plasse L; Paris S; Poirier J
    Lancet; 1985 Nov; 2(8466):1213-6. PubMed ID: 2866293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hydroxylation of debrisoquin in Parkinson's disease].
    Meillard MN; Bentué-Ferrer D; Brunet-Bourgin F; Morel G; Allain H
    Presse Med; 1990 May; 19(20):947-9. PubMed ID: 2141131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative polymorphism of debrisoquine in Parkinson's disease.
    Benitez J; Ladero JM; Jimenez-Jimenez FJ; Martinez C; Puerto AM; Valdivielso MJ; Llerena A; Cobaleda J; Muñoz JJ
    J Neurol Neurosurg Psychiatry; 1990 Apr; 53(4):289-92. PubMed ID: 2341841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoking, cancer, and Parkinson's disease.
    Barbeau A; Roy M; Cloutier T
    Ann Neurol; 1986 Jul; 20(1):105-6. PubMed ID: 3740811
    [No Abstract]   [Full Text] [Related]  

  • 5. Debrisoquine oxidation in Parkinson's disease.
    Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E
    Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking, cancer, and Parkinson's disease.
    Golbe LI; Bernholc AA; Duvoisin RC
    Ann Neurol; 1987 May; 21(5):513. PubMed ID: 3592644
    [No Abstract]   [Full Text] [Related]  

  • 7. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
    Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
    Bordet R; Broly F; Destée A; Libersa C
    Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease.
    Gudjonsson O; Sanz E; Alván G; Aquilonius SM; Reviriego J
    Br J Clin Pharmacol; 1990 Aug; 30(2):301-2. PubMed ID: 2206793
    [No Abstract]   [Full Text] [Related]  

  • 12. Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
    Gleiter CH; Aichele G; Nilsson E; Hengen N; Antonin KH; Bieck PR
    Br J Clin Pharmacol; 1985 Jul; 20(1):81-4. PubMed ID: 4027140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquine hydroxylation in Parkinson's disease.
    Steiger MJ; Lledo P; Quinn NP; Marsden CD; Turner P; Jenner PG
    Acta Neurol Scand; 1992 Aug; 86(2):159-64. PubMed ID: 1414226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer.
    Ohta S; Tachikawa O; Makino Y; Tasaki Y; Hirobe M
    Life Sci; 1990; 46(8):599-605. PubMed ID: 2308469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
    Brøsen K; Gram LF; Haghfelt T; Bertilsson L
    Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interethnic dissociation between debrisoquine and desipramine hydroxylation.
    Rudorfer MV; Lane EA; Potter WZ
    J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
    Arvela P; Kirjarinta M; Kirjarinta M; Kärki N; Pelkonen O
    Br J Clin Pharmacol; 1988 Nov; 26(5):601-3. PubMed ID: 3207564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation.
    Alvan G; von Bahr C; Seidemann P; Sjöqvist F
    Lancet; 1982 Feb; 1(8267):333. PubMed ID: 6120324
    [No Abstract]   [Full Text] [Related]  

  • 19. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications.
    Bertilsson L; Mellström B; Sjökvist F; Mårtenson B; Asberg M
    Lancet; 1981 Mar; 1(8219):560-1. PubMed ID: 6111662
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
    Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
    Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.